logo

For the Inventor, By the Inventor

Munchenstein, Switzerland

Benoit Pugin

This inventor holds 20 USPTO granted patents and 3 published patent applications, plus 4 CIPO patents, primarily in Catalytic Chemistry. Top assignees: Ciba-Geigy Corporation, Novartis Ag, Destiny Pharma Limited. Active years: 1991-2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Benoit Pugin. Retrieved from https://idiyas.com/inventor/benoit-pugin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 20 

% Patents Active = 90.0


Average Co-Inventor Count = 2.1

ph-index = 8

Forward Citations = 151(Granted Patents)


Location History:

  • Muchenstein, CH (2000)
  • M{umlaut over (u)}nchenstein, CH (2001)
  • Muenchenstein, CH (2007 - 2011)
  • Munchenstein, CH (1991 - 2013)

Company Filing History:

goldMedal9 out of 6,858 
 
Ciba-Geigy Corporation
 patents
silverMedal4 out of 3,978 
 
Novartis Ag
 patents
bronzeMedal2 out of 5 
 
Destiny Pharma Limited
 patents
4. 2 out of 166 
 
Novartis Corporation
 patents
5. 2 out of 36 
 
Solvias Ag
 patents
6. 1 out of 18 
 
Merck & Cie
 patents
7. 1 out of 126 
 
Novartis Finance Corporation
 patents
where one patent can have more than one assignee

Years Active: 1991-2013

Loading Chart...
Loading Chart...
Areas of Expertise:
Chiral Ligands
Photodynamic Therapy
Ferrocenyl Compounds
Tetrahydropterins
Optically Pure
Diphosphines
Silylated Compounds
Asymmetric Addition
Aminobenzonitriles
Stereospecific Hydrogenation
Optically Active Amines
Ferrocenyldiphosphines
20 patents (USPTO):Explore Patents
1. 8598371 - Bidentate chiral ligands for use in catalytic asymmetric addition reactions (2013-12-03),
2. 8084602 - Porphyrin derivatives and their use in photodynamic therapy (2011-12-27),
3. 7816525 - Process for the preparation of optically pure tetrahydropterins and derivatives, and specifically of optically pure tetrahydrofolic acid and derivatives thereof, by stereospecific hydrogenation (2010-10-19),
4. 7244841 - Porphyrin derivatives and their use in photodynamic therapy (2007-07-17),
5. 6169192 - Functionalized ferrocenyldiphosphines, a process for their preparation and their use (2001-01-02),
6. 6133464 - Chiral ferrocenyls (2000-10-17),
7. 6015919 - Dihalogenated ferrocenes and processes for the preparation thereof (2000-01-18),
8. 5925778 - Dihalogenated ferrocenes and processes for the preparation thereof (1999-07-20),
9. 5883283 - Process for the preparation of substituted 3-aminobenzonitriles (1999-03-16),
10. 5783715 - Silylated ferrocenyldiphosphines, silylated ferrocenyldiphosphines bound (1998-07-21),
11. 5777062 - Diphosphines bonded to side chains of polymers, and metal complexes (1998-07-07),
12. 5627293 - Silylated ferrocenyldiphosphines, silylated ferrocenyldiphosphines bound (1997-05-06),
13. 5432289 - Diphosphines containing silane groups, immobilized diphosphines and the (1995-07-11),
14. 5382729 - Diphosphines containing silane groups, immobilized diphosphins and the (1995-01-17),
15. 5308819 - Diphosphines containing silane groups, immobilised diphosphines and the (1994-05-03),

Title: Benoit Pugin: Innovator in Catalysis and Photodynamic Therapy

Introduction

Benoit Pugin, hailing from Munchenstein, Switzerland, is a prominent innovator known for his significant contributions to the fields of catalysis and medical therapies. With an impressive portfolio of 20 patents, Pugin has made considerable advancements that highlight his expertise and dedication to scientific innovation.

Latest Patents

Among his notable patents, Pugin has developed bidentate chiral ligands useful in catalytic asymmetric addition reactions. The compounds, identified by the formula (I), are designed to predominantly favor one diastereomer or exist as pure diastereomers. Additionally, he has explored porphyrin derivatives which serve critical roles in photodynamic therapy. His inventions facilitate the treatment of medical conditions requiring photodynamic agents, including pharmaceutical formulations, sterilizing solutions, and methods of treatment involving these compounds.

Career Highlights

Throughout his career, Benoit Pugin has worked with renowned companies, including Ciba-Geigy Corporation and Novartis AG. His time at these organizations has played a crucial role in shaping his research and innovative output, allowing him to lead projects that bridge the gap between chemical science and practical medical applications.

Collaborations

Pugin has collaborated with notable colleagues such as Felix Spindler and Manfred Muller, contributing to a dynamic exchange of ideas and fostering innovative approaches within his field. These collaborations have enabled him to broaden his research capabilities and enhance the impact of his patents.

Conclusion

Benoit Pugin stands out as a leading inventor, pushing the boundaries of chemical applications in both catalysis and medicine. His 20 patents reflect his commitment to innovation and his ability to translate complex scientific concepts into practical solutions, ultimately benefiting various sectors of society.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…